TMC Radiation Oncology

@sudeeksh_garg For all patient related queries, we direct you to our teleconsult services: WhatsApp: 9321470561 Email: teleconsult@tmc.gov.in Else please contact our reception desk 022-24177000 extension 6050 during working hours

Sharing practical flow cytometry videos from Department of Hematopathology @ACTREC_TMC for real-world laboratory use. We hope these resources help colleagues & trainees enhance quality & standardization in clinical flow cytometry practice tinyurl.com/3c5wtce4 #FlowCytometry

85 years of care, compassion, and commitment. Since 1941, @TataMemorial has remained dedicated to accessible cancer care, advancing research, and training the next generation of oncology professionals. Honouring the legacy. Renewing the commitment. #85YearsOfCare #FoundationDay

85th Hospital Day of Tata Memorial Hospital #EBM 2026 @TataMemorial @RadOncTMC @RimaPathak1

Tata Memorial Centre’s nationwide network was created with one goal: to ensure that world-class cancer care is accessible to all irrespective of geographical and economic limitations.

MEMENTO study protocol published in @BioMedCentral RCT investigating the role of memantine in craniospinal irradiation for improving neurocognitive function. Study enrolling fast with >50% accrual completed @RadOncTMC @ACTREC_TMC @TataMemorial rdcu.be/e5IbS

Study protocol of proton RCT in primary brain tumors (PRIDE) published in @BioMedCentral Radiation Oncology, with study accrual ongoing ahead of schedule @RadOncTMC @ACTREC_TMC @TataMemorial @PTCOG_Official rdcu.be/e34AG

On International Childhood Cancer Day, we recognise the power of sustained support in changing the trajectory of childhood cancer care. @pho_india @TMC_Varanasi

100 m and 200m 🏃‍♀️ 🥉 @JifmiM 200 m 🏃‍♂️ 🥇@GowthamSuryaKr1 🥉 @u_subramanya 400 m 🏃‍♂️ 🥉 @GowthamSuryaKr1 400 m 🏃‍♀️ 🥉 Dr Avni Garg 400 m Relay 🏃‍♀️🏃‍♀️🏃‍♀️🏃‍♀️ 🥉 @makandcheese_28, Dr Swarnamanjari, Dr Akanksha Lankada, Dr Avni Garg Relay 50 mt x 4 Freestyle 🏊‍♀️ 🥉 Dr Lokesh S

Women’s Singles 🏸 🥉 @makandcheese_28 Chess♟️ 🥇 Dr Arunava Bandhopadhyay Carrom Singles 🥇 @harshDEEP2540 🥈 @pratik_devde Carrom Doubles 🥇 @pratik_devde Carrom Mixed Doubles 🥇 @harshDEEP2540

Proud of our @RadOncTMC team for their stellar performance at #CONQUEST2026! Team events Futsal 🥈 Basketball 🥈 Volleyball 🥈

Radiotherapy for Sino-nasal Tumors Pre-Conference Workshop | EBM 2026 @TataMemorial A focused, case-based academic update on one of the most challenging sites in head and neck oncology. 26 Feb 26 @TataMemorial, Mumbai 🔗 tinyurl.com/7jehde9p Don't miss the opportunity!

Tata Memorial Centre announces the XXIV Annual Conference – Evidence Based Management of Cancers in India (EBM 2026). February 27 – March 1, 2026 Tata Memorial Hospital, Prof. R. D. Choksi Auditorium, Parel, Mumbai Register: tmc.gov.in/CRS/Conference…

Dear Colleagues We are pleased to share details of the 24th Annual Meeting EBM 2026. Online Registration Link: - tmc.gov.in/m_events/Event… Conference Webpage: - tmc.gov.in/CRS_Conference… Warm regards, EBM 2026 Organizing Committee Tata Memorial Centre

Join us for the Annual Evidence Based Management Conference 2026 at Tata Memorial Centre on Head Neck Cancers

A little belated 🎄Christmas present🎁 for those who treat penile cancer! Check out these long-term outcomes for adjuvant RT (+/- chemo) in penile cancer! Disease severity • 93% node-positive 🔴 • 76.7% pN3 ⚠️& with ENE • Median tumor size: 4.0 cm Survival outcomes ⏱️📈 • Median overall survival (OS): 77.2 months 🕰️ • 5-year OS: 52% 🎯 • 7-year OS: 46% • Median recurrence-free survival (RFS): not reached 🚫 • 5-year RFS: 66% ✅ Recurrence patterns 🔁⚠️ (26.6% overall) • 8/30 patients recurred  ▫️ 6 locoregional (20%) 📍  ▫️ 2 distant (6.6%, lung metastases) 🫁 • Prepubic fat recurrence in 25% of all recurrences (2/8) 👀➡️ an under-recognized failure site Toxicity profile 💊🩺 • RT generally well tolerated 👍 • Lymphedema most common late toxicity (Grade 2 in ~60%) 🦵 🧠 Bottom line 💡⚡ Even with adjuvant RT, locoregional failure remains the dominant mode of relapse in high-risk penile cancer 🤔Should we rethink our treatment volumes? @ASTRO_org advancesradonc.org/article/S2452-…

Our new study in @Nature @pcan_journal We report progression patterns in de novo oligo HSPC staged with PSMA-PET, treated with prostate but no MDT This allowed us to observe the natural history of PSMA defined oligometastatic disease. Fill paper link rdcu.be/eT7xw

WPRT? Proton therapy? Both have been under fire lately in Prostate cancer. Instead of debating, we got data, and made a new start. This is the first peer-reviewed report of SBPT to prostate + whole pelvis using proton therapy. @ctRO_journal @ACTREC_TMC @ApolloProton

Breakthrough! Our GWAS on Buccal Mucosa Cancer reveals a new 6q27 locus, TERT signal, tobacco–gene interaction, PD-1/IFN-γ pathways, and the world’s first germline NOTCH1 polymorphism linked to oral cancer. Full paper: authors.elsevier.com/sd/article/S23…